Immune Camouflage in Pythium insidiosum Keratitis: A Hypothesis on Molecular Mimicry and Host Pattern Recognition Receptor Evasion

Pythium insidiosum keratitis is a vision-threatening corneal infection that often mimics fungal keratitis, yet it responds poorly to standard antifungals. Historically, approximately 80% of cases have required surgical excision of the cornea. Unlike fungi, <i>P. insidiosum</i> lacks ergosterol in its cell membrane and possesses a cellulose-rich wall with minimal β-1,3-glucan exposure, reducing Dectin-1-mediated detection. Surface hydroxyproline-rich glycoproteins structurally resemble host collagen, potentially engaging inhibitory lectin receptors and dampening early innate immune responses. Delayed Toll-like receptor (TLR4) activation, limited TLR2 signaling, and altered complement activation contribute to subdued inflammatory recruitment, allowing the pathogen to establish deep stromal infection before overt clinical signs emerge. We hypothesize that the organism's aggressive behaviour stems from immune camouflage. <i>P. insidiosum</i> evades early host immune detection by masking its pathogen-associated molecular patterns (PAMPs) and mimicking host molecules. This allows the oomycete to establish infection with minimal initial inflammation. Supporting evidence includes the atypical, cellulose-rich cell wall (with minimal β-glucan and no ergosterol) of <i>P. insidiosum</i> blunts early cytokine responses. Moreover, the corneal cells infected with Pythium initially produce very low levels of IL-1β, underscoring the potential need for adjunctive immunotherapies to effectively clear the infection. If validated, this immuno-evasion hypothesis has major implications: diagnostic assays could incorporate host immune response patterns, and novel treatments might combine cell wall-degrading enzymes or Pattern Recognition Receptor (PRR) agonists with immunotherapy to "unmask" the pathogen for immune elimination. Ultimately, viewing <i>P. insidiosum</i> as an immuno-camouflaged pathogen offers a new paradigm to explain its clinical course and to improve outcomes in this often-devastating keratitis.